Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

UNVERIFIED PROFILE

Are you Sai-Hong Ignatius Ou?   Register this Author

Register author
Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

Publications by authors named "Sai-Hong Ignatius Ou"

Are you Sai-Hong Ignatius Ou?   Register this Author

100Publications

4307Reads

40Profile Views

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.

Trends Cancer 2019 Nov 29;5(11):677-692. Epub 2019 Oct 29.

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2019.09.008DOI Listing
November 2019

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.

Clin Lung Cancer 2019 Sep 26. Epub 2019 Sep 26.

Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.09.004DOI Listing
September 2019

Neuregulin 1 Fusion-Positive NSCLC.

J Thorac Oncol 2019 08 22;14(8):1354-1359. Epub 2019 May 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.05.015DOI Listing
August 2019

CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.

Lung Cancer 2019 04 22;130:201-207. Epub 2019 Feb 22.

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, Orange County, CA, 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.02.025DOI Listing
April 2019

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification.

Lung Cancer (Auckl) 2019 12;10:21-26. Epub 2019 Mar 12.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S190403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586PMC
March 2019

Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.

Clin Lung Cancer 2019 01 21;20(1):e77-e80. Epub 2018 Sep 21.

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.09.006DOI Listing
January 2019

Dramatic response to alectinib in a lung cancer patient with a novel fusion and an acquired ALK T1151K mutation.

Lung Cancer (Auckl) 2018 8;9:111-116. Epub 2018 Nov 8.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S186804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234987PMC
November 2018

Pacific Rim redux: lorlatinib, the ultimate Jaeger?

Ann Transl Med 2018 Nov;6(Suppl 1):S40

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://atm.amegroups.com/article/view/21777/21832
Publisher Site
http://dx.doi.org/10.21037/atm.2018.09.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291554PMC
November 2018

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

J Clin Oncol 2018 09 16;36(26):2693-2701. Epub 2018 May 16.

D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Dae Ho Lee, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Corey J. Langer, University of Pennsylvania, Philadelphia, PA; Alice T. Shaw, Massachusetts General Hospital, Boston; William Reichmann, Jeff Haney, Tim Clackson, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; Rudolf M. Huber, University Hospital of Munich, Munich, Germany; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Lyudmila A. Bazhenova and Kathryn A. Gold, University of California San Diego Moores Cancer Center, La Jolla; Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Irvine, CA; Howard L. West, Swedish Cancer Institute, Seattle, WA; and Scott N. Gettinger, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.5841
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.5841DOI Listing
September 2018

Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.

Lung Cancer 2018 09 6;123:83-86. Epub 2018 Jul 6.

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200032, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.07.004DOI Listing
September 2018

Liquid Biopsy to Identify Actionable Genomic Alterations.

Am Soc Clin Oncol Educ Book 2018 May;38:978-997

From Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Karmanos Cancer Center, Wayne State University, Detroit, MI; Hematology/Oncology Section, Veterans Affairs Long Beach Healthcare System, Long Beach, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_199765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865813PMC
May 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Lung Cancer (Auckl) 2017 6;8:241-247. Epub 2017 Dec 6.

Department of Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/cis-oriented-solvent-front-egfr-g7
Publisher Site
http://dx.doi.org/10.2147/LCTT.S147129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122PMC
December 2017

ASCEND-5: too little too late?

J Thorac Dis 2017 Oct;9(10):3477-3479

Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.08.147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723760PMC
October 2017

Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 08 11;35(22):2463-2466. Epub 2017 May 11.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.1323DOI Listing
August 2017

METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?

J Thorac Oncol 2017 08;12(8):1180-1182

Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.06.009DOI Listing
August 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Lung Cancer 2017 04 9;106:110-114. Epub 2017 Feb 9.

Department of Medicine, Division of Hematology-Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.005DOI Listing
April 2017

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

J Thorac Oncol 2017 01 21;12(1):141-144. Epub 2016 Sep 21.

Clinical Oncology, Cancer Institute of the State of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.116DOI Listing
January 2017

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.

J Thorac Oncol 2017 01 28;12(1):152-156. Epub 2016 Sep 28.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.127DOI Listing
January 2017

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 01 30;12(1):145-151. Epub 2016 Sep 30.

Birmingham Veterans Administration Hospital, Birmingham, Alabama; University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.131DOI Listing
January 2017

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

J Thorac Oncol 2017 01 26;12(1):15-26. Epub 2016 Oct 26.

University of Colorado Cancer Center, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603268PMC
January 2017

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

Lung Cancer 2017 01 15;103:27-37. Epub 2016 Nov 15.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange County, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.11.011DOI Listing
January 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

ASCEND-2: a canary in a coal mine for descending to second-line treatment for -rearranged non-small cell lung cancer.

Transl Lung Cancer Res 2016 Dec;5(6):660-664

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.12.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233869PMC
December 2016

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

J Thorac Oncol 2016 09 22;11(9):1493-502. Epub 2016 Jun 22.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.004DOI Listing
September 2016

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Drug Des Devel Ther 2015 15;9:5641-53. Epub 2015 Oct 15.

National University Health System and Cancer Science Institute of Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S52787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610796PMC
July 2016

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Lung Cancer 2016 07 22;97:48-50. Epub 2016 Apr 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.013DOI Listing
July 2016

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

Lung Cancer 2016 06 26;96:15-8. Epub 2016 Mar 26.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.03.008DOI Listing
June 2016

Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.

Adv Exp Med Biol 2016 ;893:179-187

MUSC Hollings Cancer Center, Department of Medicine, Division of Hematology-Oncology, Medical University of South Carolina College of Medicine, Charleston, SC, 29403, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-24223-1_9DOI Listing
May 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

J Clin Oncol 2016 Mar 23;34(7):661-8. Epub 2015 Nov 23.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA; Jin Seok Ahn, Sungkyunkwan University School of Medicine; Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan; Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia; Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes; Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France; Alessandra Bearz, National Cancer Institute, Aviano, Italy; Santiago Viteri Ramirez, Quiron-Dexeus University Hospital, Barcelona, Spain; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; and Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/jco.2015.63.9443DOI Listing
March 2016

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.

J Thorac Oncol 2016 Mar;11(3):281-3

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.01.005DOI Listing
March 2016

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Lung Cancer 2016 Feb 3;92:19-21. Epub 2015 Dec 3.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.11.023DOI Listing
February 2016

MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Transl Lung Cancer Res 2015 Dec;4(6):820-4

1 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Tungpayathai, Ratchathewee, Bangkok 10400, Thailand ; 2 Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700217PMC
December 2015

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Oncologist 2015 Oct 1;20(10):1175-81. Epub 2015 Sep 1.

Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591939PMC
October 2015

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Transl Lung Cancer Res 2015 Oct;4(5):649-52

1 Department of Medicine, Division of Hematology-Oncology, 2 Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630509PMC
October 2015

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

Darkness before dawn, but will the sun always rise?

Cancer 2015 Aug 17;121(15):2514-6. Epub 2015 Apr 17.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29388DOI Listing
August 2015

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Lung Cancer 2015 Jun 30;88(3):355-9. Epub 2015 Mar 30.

Hoag Neurosciences Institute, Director, Hoag Brain Tumor Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92663, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.03.022DOI Listing
June 2015

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

Chin Clin Oncol 2015 Jun;4(2):20

Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://www.thecco.net/article/view/6520/7543
Publisher Site
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.05.03DOI Listing
June 2015

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Lung Cancer 2015 May 12;88(2):231-4. Epub 2015 Feb 12.

USC Norris Comprehensive Cancer Center and Hospital, Department of Medicine, Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.02.005DOI Listing
May 2015

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Oncologist 2015 May 16;20(5):499-507. Epub 2015 Apr 16.

Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425384PMC
May 2015

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.

Oncologist 2015 Mar 5;20(3):307-15. Epub 2015 Feb 5.

Izumi Municipal Hospital, Osaka, Japan; Nagoya University Hospital, Nagoya, Aichi, Japan; Miyagi Cancer Center, Miyagi, Japan; University of Kansas Cancer Center, Kansas City, Kansas, USA; National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan; National Hospital Organization Nagoya Medical Center, Aichi, Japan; Aichi Medical University School of Medicine, Nagoya, Aichi, Japan; Graduate School of Medicine, Osaka City University, Osaka, Japan; Koyo Hospital, Wakayama, Japan; Catalan Institute of Oncology, Barcelona, Spain; Kansai Medical University Hirakata Hospital, Osaka, Japan; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350797PMC
March 2015

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lung Cancer 2015 Feb 19;87(2):207-9. Epub 2014 Dec 19.

Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States; Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.12.011DOI Listing
February 2015

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Oncologist 2015 Feb 7;20(2):224-6. Epub 2015 Jan 7.

Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319629PMC
February 2015

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

J Thorac Oncol 2015 Feb;10(2):387-91

*Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; †SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Medicine, Arizona Cancer Center, University of Arizona Tucson School of Medicine, Tucson, AZ; §Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; ║Fox Chase Cancer Center, Philadelphia, PA; ¶Department of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and #Department of Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304604PMC
February 2015

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

J Thorac Oncol 2014 Dec;9(12):1821-5

*Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000368DOI Listing
December 2014

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.

Lancet Respir Med 2014 Dec 19;2(12):966-8. Epub 2014 Nov 19.

Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology; University of California Irvine School of Medicine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(14)70259-0DOI Listing
December 2014

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.

Oncologist 2014 Sep 5;19(9):1008-10. Epub 2014 Aug 5.

Chao Family Comprehensive Cancer Center and Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153456PMC
September 2014

To the editor.

J Thorac Oncol 2014 Jul;9(7):e57-8

Medicine-Hematology-Oncology, Chao Family Comprehensive Cancer Center, Irvine, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153034
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000192DOI Listing
July 2014